Amyloid alone does not confirm that Alzheimer's disease is progressing rapidly. Here's what people need to know about the ...

Some researchers seek to establish a single abnormal result on a set of biomarker-based tests as sufficient to diagnose the ...

Every anti-amyloid antibody is different, hence the donanemab AUR address two unique aspects of this drug: in its Phase 3 trial, scientists used baseline tau PET scans to determine eligibility, and ...

The memorandum of understanding (MOU) between the companies aims to advance the development of imaging agents used in PET ...

Roche put forward new data on two of its upcoming, non-invasive blood tests designed to help rule out a diagnosis of ...

Pharmaceuticals presented updated data on a validated research-use plasma pTau217 assay to screen potential participants in the ...

requiring patients that fall into this zone follow up with cerebral spinal fluid measurement via invasive lumbar puncture or costly amyloid PET scans. LucentAD Complete addresses this by reducing ...

Lucent Diagnostics, a brand of Quanterix Corporation (NASDAQ: QTRX), has introduced LucentAD Complete, a new multi-marker blood test designed to help detect Alzheimer’s Disease (AD) in a broader range ...

The science around dementia and Alzheimer's disease has grown over the past two decades. Thousands of area residents have ...

When I co-invented the first PET (positron emission tomography) scan to visualize brain amyloid and tau—the physical evidence of Alzheimer’s disease—I did not foresee the distressing mental ...

Lucent Diagnostics, a brand of Quanterix Corporation, has introduced LucentAD Complete, a new multi-marker blood test designed to help detect Alzheimer’s Disease (AD) in a broad ...

Eli Lilly Saudi Arabia and King Faisal Specialist Hospital & Research Centre (KFSHRC) have teamed up to make KFSHRC’s Neuroscience Centre a top regional hub for Alzheimer’s disease treatment.